Research Paper Volume 12, Issue 19 pp 19641—19659

Figure 6. Clinical utility of stromal cell content-related prognostic DEG panel and stromal score. (A) Overall survival, disease-free survival, cancer-specific survival, and progression-free survival of patients between high- and low-risk groups based on stromal cell content-associated prognostic genes. (B) ROC curve analysis of risk score relative to clinicopathological features (age, gender, pathologic grade, clinical stage, tumor stage, lymph node metastasis and distant metastasis). (C, D) Differential risk scores, survival status and expression pattern of 17 IRGs in HCC patients. (E, F) Univariate and multivariate Cox regression analysis showing the independent prognostic value of this risk score. (G) Relationship between risk score and the clinical stage, as well as the T stage of HCC patients. (H) Relationships between genes in the prognostic DEG panel and the clinicopathological characteristics of HCC patients. (I) Pearson correlation analysis between the stromal score and infiltration abundances of immune cells. (J) Spearman correlation analysis between the risk score and TMB. (K) Spearman correlation analysis between the risk score and MSI. (L) Heatmap visualization of the expression of 4 DNA MMR genes related to the risk score. *** p = <0.001.